Provectus reports progress in PV-10 program for metastatic melanoma

November 14, 2015

???Furthermore, other than offering improved treatment options for triple-negative breast cancer, iniparib could be exploited in other tumour types that express known defective DNA repair enzymes. In lung cancer, for example, mutations in DNA repair enzymes, including BRCA-1 have been linked with different levels of sensitivity to chemotherapy or radiotherapy.???

In spite of the positive data to date, it should be noted that strong conclusions on the drug??s efficacy cannot be made based on this Phase II trial, which is limited by the small patient number and the fact that its primary endpoint was clinical benefit response rather than progression-free or overall survival.

By the end of 2010, Datamonitor estimates that 484,600 women will be diagnosed with breast cancer in the seven major markets** during the year. Between 2010 and 2019 total breast cancer incident cases in the seven major markets are forecasted to increase by 13% to 548,000 annual incident cases by the end of 2019.

www.datamonitor